[go: up one dir, main page]

MA52199A - Compositions et procédés de traitement de la dystrophie maculaire - Google Patents

Compositions et procédés de traitement de la dystrophie maculaire

Info

Publication number
MA52199A
MA52199A MA052199A MA52199A MA52199A MA 52199 A MA52199 A MA 52199A MA 052199 A MA052199 A MA 052199A MA 52199 A MA52199 A MA 52199A MA 52199 A MA52199 A MA 52199A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
macular dystrophy
dystrophy
Prior art date
Application number
MA052199A
Other languages
English (en)
Inventor
Robert Maclaren
De La Camara Cristina Martinez-Fernandez
Gregory S Robinson
Original Assignee
Nightstarx Ltd
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nightstarx Ltd, Univ Oxford Innovation Ltd filed Critical Nightstarx Ltd
Publication of MA52199A publication Critical patent/MA52199A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA052199A 2018-04-05 2019-04-05 Compositions et procédés de traitement de la dystrophie maculaire MA52199A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05

Publications (1)

Publication Number Publication Date
MA52199A true MA52199A (fr) 2021-02-17

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052199A MA52199A (fr) 2018-04-05 2019-04-05 Compositions et procédés de traitement de la dystrophie maculaire

Country Status (21)

Country Link
US (2) US20190307900A1 (fr)
EP (1) EP3775233A1 (fr)
JP (1) JP2021520232A (fr)
KR (1) KR20210005040A (fr)
CN (1) CN113056561A (fr)
AU (1) AU2019247864A1 (fr)
BR (1) BR112020020204A2 (fr)
CA (1) CA3096088A1 (fr)
CL (1) CL2020002561A1 (fr)
CO (1) CO2020013690A2 (fr)
EA (1) EA202092069A1 (fr)
IL (1) IL277779A (fr)
JO (1) JOP20200253A1 (fr)
MA (1) MA52199A (fr)
MX (1) MX2020010477A (fr)
PE (1) PE20210918A1 (fr)
PH (1) PH12020551641A1 (fr)
RU (1) RU2020132890A (fr)
SG (1) SG11202009759SA (fr)
TW (1) TW202003052A (fr)
WO (1) WO2019195727A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383587B2 (en) 2018-10-25 2025-08-12 Takeda Pharmaceutical Company Limited AAV triple-plasmid system
WO2020140007A1 (fr) * 2018-12-28 2020-07-02 University Of Rochester Thérapie génique pour mutations dominantes best1
CA3168365A1 (fr) * 2020-02-28 2021-09-02 The Trustees Of The University Of Pennsylvania Traitement de bestrophinopathies dominantes autosomiques et procedes d'evaluation de celles-ci
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
EP4590841A2 (fr) * 2022-09-20 2025-07-30 Aldevron, LLC Vecteurs de best1 et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153563A1 (fr) * 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Purification de virus
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
WO2015075154A2 (fr) * 2013-11-20 2015-05-28 Fondazione Telethon Protéines artificielles se liant à l'adn et leurs utilisations
MX379027B (es) * 2013-12-06 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para la expresion de un polinucleotido de interes en el epitelio pigmentario retiniano de un sujeto.
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
BR112017018728A2 (pt) * 2015-03-03 2018-04-17 Fond Telethon sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
WO2017083722A1 (fr) * 2015-11-11 2017-05-18 Greenberg Kenneth P Compositions crispr et leurs méthodes d'utilisation pour la thérapie génique

Also Published As

Publication number Publication date
CL2020002561A1 (es) 2021-04-23
US20230149566A1 (en) 2023-05-18
MX2020010477A (es) 2021-03-02
KR20210005040A (ko) 2021-01-13
US20190307900A1 (en) 2019-10-10
AU2019247864A1 (en) 2020-10-22
TW202003052A (zh) 2020-01-16
IL277779A (en) 2020-11-30
JP2021520232A (ja) 2021-08-19
JOP20200253A1 (ar) 2020-10-04
EA202092069A1 (ru) 2021-03-12
WO2019195727A1 (fr) 2019-10-10
CN113056561A (zh) 2021-06-29
PE20210918A1 (es) 2021-05-19
SG11202009759SA (en) 2020-10-29
BR112020020204A2 (pt) 2021-01-19
CA3096088A1 (fr) 2019-10-10
CO2020013690A2 (es) 2021-04-19
EP3775233A1 (fr) 2021-02-17
RU2020132890A (ru) 2022-05-06
PH12020551641A1 (en) 2021-07-26

Similar Documents

Publication Publication Date Title
EP3720448A4 (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3496739A4 (fr) Compositions et procédés de traitement de l'hypertension pulmonaire
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA47613A (fr) Compositions et procédés de traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3612215A4 (fr) Compositions et procédés pour le traitement d'inflammation pulmonaire
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
EP3389672A4 (fr) Compositions et procédés de traitement de maladies hépatiques
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP3448421A4 (fr) Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
EP3389657A4 (fr) Procédés de traitement de l'hyperalgésie
EP3289064A4 (fr) Compositions et procédés pour la détection d'allergènes
MA55087A (fr) Compositions et procédés de traitement de laminopathies
EP3405172A4 (fr) Procédés et compositions pour le traitement du vieillissement cutané
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii
EP3403099A4 (fr) Procédés et compositions pour le traitement du cancer
EP3801590A4 (fr) Compositions et procédés de traitement du psoriasis